Navigation Links
Three Astex Drug Candidates to be Presented at the 2007 American Society of Hematology Annual Meeting
Date:11/29/2007

CAMBRIDGE, England, November 29 /PRNewswire/ -- Astex Therapeutics Ltd. today announced that data on its drug candidates AT9283, AT7519 and AT9311 will be presented at the American Society of Hematology's 49th Annual Meeting and Exposition, 8-11th December 2007, at the Georgia World Congress Center, Atlanta, Georgia.

AT9283 is an inhibitor of the kinases Aurora A, Aurora B, JAK2, BCR-Abl and Flt-3. There is strong evidence for an important role of each of these kinases in the development or progression of a variety of cancers. AT9283 is currently being investigated in three multi-centre clinical trials, including a Phase I/II study in patients with refractory haematological malignancies.

AT7519 is a selective inhibitor of certain Cyclin Dependent Kinases (CDKs), currently in two multi-centre Phase 1 clinical trials.

AT9311 (also known as NVP-LCQ195) is also an inhibitor of CDKs, but with a pharmacological profile that is markedly different from that of AT7519. Astex is developing AT9311 in collaboration with Novartis.

Astex discovered all of these compounds using its proprietary fragment-based drug discovery platform Pyramid(TM).

"Astex has discovered and is developing a number of products that may have promise in the treatment of a wide range of life-threatening haematological diseases. Together with investigators from the M.D. Anderson Cancer Center and the UAB Comprehensive Cancer Center, we are reporting for the first time that one of these, AT9283, has already shown early signs of clinical efficacy as a single agent in the treatment of advanced refractory AML and CML," said Harren Jhoti, Chief Scientific Officer and Executive Vice President of Astex.

Hagop Kantarjian, Chairman of the Department of Leukemia at M.D. Anderson, Principal Investigator in the Phase I/II study of AT9283, said, "We see preliminary evidence of the anti-leukemic activity of AT9283 at well-tolerated doses in patients with relapsed and refra
'/>"/>

SOURCE Astex Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. KGI Elects Three New Members to Board of Trustees
2. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
3. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
4. Weil Gotshal Wins Major Victory for Applera; Secures Summary Judgment Invalidating Three Patents
5. European Union has Three-Speed Healthcare System - Many Countries Lagging in Reform
6. Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference
7. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
8. Pharmasset to Present at Three Investor Conferences in November 2007
9. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
10. Martek to Obtain Permanent Injunction Against Lonza in U.S. Patent Infringement Suit; Jury Verdict on Infringement of Two of Three Patents Upheld by Judge
11. Gen-Probe to Webcast Three Upcoming Presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2013)... SANTA CLARA, Calif. , Dec. 9, 2013 ... measurement and control solutions for life sciences process ... Universal™ SmartControllers for upstream cell culture and fermentation.  ... and simplify process scale-up using bioreactors from different ... work with stirred-tank single-use vessels from most major ...
(Date:12/9/2013)... , Dec. 9, 2013 Spherix ... to the fostering and monetization of intellectual ... subsidiary Guidance IP LLC filed suit on December ... Mobility LLC (collectively "Defendants") for infringement of ... for Determining the Geolocation of a Transmitter." Guidance ...
(Date:12/8/2013)... 2013 Die King Abdulaziz City ... Leistungsträger Saudi-Arabiens, und die Life Technologies Corporation ... The Saudi Human Genome Program an ... Basis aller Krankheiten im Königreich Saudi-Arabien und im ... zur bestmöglichen Personalisierung der Gesundheitsversorgung in Saudi-Arabien genutzt ...
(Date:12/6/2013)... (PRWEB) December 06, 2013 JCB ... the standard for environmental monitoring with the installation ... Worldwide Solutions. The pharmacy’s latest improvement is a ... new regulatory oversight to the compounding industry. , ... priorities, and we are constantly reinvesting in process ...
Breaking Biology Technology:Finesse Solutions Launches Next Generation G3Pro Universal SmartControllers to Enhance Productivity in Pilot and Production Scale Cell Culture 2Spherix's Wholly Owned Subsidiary Sues AT&T Inc. and AT&T Mobility for Infringement of Patent for Geolocation of Cell Phones in Second Cell Phone Location Suit for Spherix 2Spherix's Wholly Owned Subsidiary Sues AT&T Inc. and AT&T Mobility for Infringement of Patent for Geolocation of Cell Phones in Second Cell Phone Location Suit for Spherix 3Saudis können auf Wunsch ihr eigenes Erbgut sequenzieren lassen, um das Gesundheitswesen des Königreichs Saudi-Arabien grundlegend zu verändern 2Saudis können auf Wunsch ihr eigenes Erbgut sequenzieren lassen, um das Gesundheitswesen des Königreichs Saudi-Arabien grundlegend zu verändern 3Saudis können auf Wunsch ihr eigenes Erbgut sequenzieren lassen, um das Gesundheitswesen des Königreichs Saudi-Arabien grundlegend zu verändern 4Saudis können auf Wunsch ihr eigenes Erbgut sequenzieren lassen, um das Gesundheitswesen des Königreichs Saudi-Arabien grundlegend zu verändern 5Saudis können auf Wunsch ihr eigenes Erbgut sequenzieren lassen, um das Gesundheitswesen des Königreichs Saudi-Arabien grundlegend zu verändern 6Saudis können auf Wunsch ihr eigenes Erbgut sequenzieren lassen, um das Gesundheitswesen des Königreichs Saudi-Arabien grundlegend zu verändern 7JCB Laboratories Debuts High Tech Monitoring System That Will Further Enhance Patient Safety, Surpass Compounding Pharmacy Standards 2
... April 16 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ... its financial results for the first quarter ended March 31, ... (8:00 AM Pacific)., Dial-in information for the ... follows:, North America (toll-free): (800) 901-5247, ...
... LONDON, April 16 Pharmaceutical companies,GlaxoSmithKline and Pfizer today announced ... world-leading, specialist HIV company. , The ... product and,their pipelines with GSK holding 85% of the company ... will be marginally dilutive to GSK earnings in the first ...
... XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB , TASE: XTL) ... from The Nasdaq Stock Market ("Nasdaq") ... that the Company,s American Depository Shares ... the Company,s ADRs at the opening of trading on April ...
Cached Biology Technology:XTL Biopharmaceuticals Ltd. Receives Notification of Delisting Determination by NASDAQ Listing Qualifications Panel 2
(Date:12/9/2013)... to submit the data obtained to the European Commission ... with medical advances in this field. On 4 December ... at the Political Sciences Research Centre in Paris (CEVIPOF) ... Biobanks: the future of regenerative medicine , Today, human ... in the life sciences and medicine. The analytical data ...
(Date:12/9/2013)... cells push and pull on each other, and ... to develop properly. Now scientists at Harvard University ... forces in three-dimensional (3D) tissues and living embryos., ... could lead to new tools to diagnose cancer, ... the Wyss Institute for Biological Engineering at Harvard ...
(Date:12/9/2013)... a sheet of plastic may not bring it to life ... experiments at Rice University. , The materials created by ... flat slabs, but they morph into shapes that can be ... research is the subject of a new paper in the ... Materials that can change their shape based on environmental conditions ...
Breaking Biology News(10 mins):EUCelLEX Project: Assessment of the social issues raised by the use of regenerative medicine in Euro 2EUCelLEX Project: Assessment of the social issues raised by the use of regenerative medicine in Euro 3Measuring life's tugs and nudges 2Measuring life's tugs and nudges 3Morphing material has mighty potential 2
... Humans and animals are able to perceive even ... ion channels play a crucial role in the mediation ... cell membrane which are highly responsive to external signals. ... allow ions (electrically charged particles), to cross the cell ...
... nutrient-rich water up from the deep ocean to boost algal ... from the atmosphere has been touted as a way of ... Andreas Oschlies of the Leibniz Institute of Marine Sciences (IFM-GEOMAR) ... "Computer simulations show that climatic benefits of the proposed geo-engineering ...
... Scientists may have just made the breakthrough of a lifetime, ... fuel to power the world,s vehicles. University of Central ... produce ethanol from waste products such as orange peels and ... current methods available to run vehicles on cleaner fuel ...
Cached Biology News:MDC researchers link protein tether to touch perception 2Ocean geoengineering scheme no easy fix for global warming 2Orange peels, newspapers may lead to cheaper, cleaner ethanol fuel 2
... is used for vertical electrophoresis applications. The cell accommodates ... L of running buffer. It includes the PROTEAN II ... kit, which contains accessories for use with 2.0 mm ... 2 sets of 20 x 20 cm glass plates, ...
... the drug discovery process in mind. Due ... Safire is the ideal instrument to bridge ... throughput screening. Safire is a fully modular ... range of high speed detection techniques. In ...
F40 piston seals are supplied as 2 seals with a seal tool to service one F40 pump of a BioLogic DuoFlow workstation....
CleanCut agarose is used to prepare genomic DNA plugs for use in pulsed field gel electrophoresis (PFGE) applications. Supplied as a 12 ml solution of 2% agarose....
Biology Products: